^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Diffuse Large B Cell Lymphoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    EHA 2023
    Title:

    FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMESFOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROMA CONSECUTIVE COHORT IN CHINA

    Published date:
    05/11/2023
    Excerpt:
    However, DH/TH and 17p/TP53 deletion were still associated with a poorer OS in the HR group ( P =0.004 and 0.014)….This is the first and largest single-center study in China to report the treatment of young DLBCL patients with risk- adapted therapy, in which IIC was applied to selected patients with clinically or biologically high-risk features and showed favorable results.
    Secondary therapy:
    Chemotherapy